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Abstract: Background: Research findings regarding the association between tricyclic antidepressant
(TCA) treatment and the risk of fracture are not consistent; we aimed to assess whether people
who take TCAs are at an increased fracture risk. Methods: Relevant studies published through
June 2020 were identified through database searches of MEDLINE, EMBASE, Scopus, PsycINFO,
ISI Web of Science, WorldCat Dissertations and Theses from each database’s inception, as well
as through manual searches of relevant reference lists. Two researchers independently performed
literature searches, study selection, data abstraction and study appraisal by using a standardized
protocol. Frequentist and Bayesian hierarchical random-effects models were used for the analysis.
The heterogeneity and publication bias were evaluated in this study. Results: Eight studies met the
inclusion criteria. Overall, TCA use was associated with a significantly increased risk of fracture in
both the frequentist approach (Risk Ratio (RR), 1.23; 95% CI, 1.06–1.42; p = 0.007) and the Bayesian
method (RR, 1.24, 95% Credible Interval (CrI), 1.01–1.56). These results were consistent in multiple
sensitivity and subgroup analyses. Significant heterogeneity was observed in the meta-analysis;
however, no significant publication bias was detected. Conclusion: TCA medication may indicate an
increased risk of fracture. TCA should be prescribed with caution in the clinic.
Keywords: fractures; tricyclic antidepressants; bone density; depression; osteoporosis; Bayesian
meta-analysis
1. Introduction
With the rapid growth of aging populations on a global scale, osteoporotic fractures have become a
critical public health concern worldwide. Globally, around 1.6 million hip fractures occur each year [1].
Additionally, fragility fractures lead to many adverse outcomes, including disability, decreased quality
of life and excess mortality [2], especially in older individuals [3]. These consequences of osteoporotic
fractures have already led to a significant increase in the social and economic burden on a global scale [4].
On the other hand, depression or depressive disorder is a prevalent mental illness, one that
affects 17.3 million adults in the United States alone [5]. A widely employed treatment for depression
is antidepressant medication, which is one of the most frequently prescribed medicines in Western
countries [6]. Tricyclic antidepressants (TCAs) were developed in the 1950s to treat depression [7].
Currently, although TCAs have been increasingly replaced by selective serotonin reuptake inhibitors
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(SSRIs) and other new safer antidepressants, they are still a good choice for some patients whose
depression has not responded to treatment with less toxic agents [8]. Previously we have demonstrated
that depression is associated with a lower bone density [9] and higher fracture risk [10]. The link
between SSRIs use and fracture risk was also examined extensively [11,12]. Many studies reported that
TCA use is significantly associated with osteoporotic fractures [13–24]; however, other studies found
that such an association was not significant [25–28]. As a result, we conducted a meta-analysis using
both cohort and case-control studies to examine the association between TCA use and fractures [24].
However, the prior meta-analysis was conducted eight years ago, and thus several large eligible cohort
studies undertaken in recent years were not included [27–31]. Therefore, an updated meta-analysis
was warranted.
This meta-analysis aimed to quantitatively assess all eligible cohort studies that examined the
effect of TCA use on fracture risk and to obtain a more comprehensive assessment and a more precise
and accurate estimate about this effect. Besides the classical frequentist method, we also employed a
Bayesian approach for this meta-analysis research, as Bayesian meta-analysis uses the probabilistic
method and can help with clinically relevant decision-making when one is confronted with uncertainty.
2. Experimental Section
We conducted this meta-analysis research using the guidelines of Meta-analysis of Observational
Studies in Epidemiology (MOOSE) [32,33]. The detailed statement of Preferred Reporting Items
for Systematic Reviews and Meta-analyses (PRISMA) was referred to when applicable. The study
objectives, primary outcomes, literature search strategy, inclusion and exclusion criteria, methods for
study selection, data extraction, and data synthesis were defined in advance in the meta-analysis
research protocol. In the protocol, we also prespecified the sensitivity and subgroup analyses we
planned to conduct.
2.1. Search Strategy and Data Sources
We conducted a comprehensive literature search of MEDLINE (from 1946) using OVID. Without
language restrictions, we used the search terms tricyclic antidepressants, antidepressant, amitriptyline,
nortriptyline, protriptyline, imipramine, desipramine, doxepin, trimipramine, fractures, osteoporosis,
osteopenia, bone density and bone (See search strategy in Appendix A). Using the same strategy, we also
conducted literature searches of EMBASE (from 1988), PsycINFO (from 1806), SCOPUS (from 1960)
and ISI Web of Science (from 1975). The above search terms were adapted for other database searches
according to the syntax of each specific database. The last literature search was conducted on 22 May
2020. The literature search with MEDLINE was automatically updated to 24 June 2020with OVID
Auto Alert. We also searched WorldCat Dissertations and Theses from its inception, as well as the
proceedings of the International Osteoporosis Foundation World Conference on Osteoporosis and
the conference abstracts of the American Society for Bone and Mineral Research from 2000 to 2020.
An experienced librarian in health science was consulted during the literature search. Two investigators
(Y.X. and Y.B.) independently examined reference lists from the original studies [23,26–31] and related
meta-analyses and reviews [24,34–37].
2.2. Study Selection
During the initial screening phase, simplified inclusion criteria were used to screen relevant
references: (1) human subjects, (2) fracture or bone mineral density (BMD) as the outcome and (3)
TCA use as exposure. Each title and abstract of each article retrieved from the electronic search was
independently reviewed by two investigators (Q.W. and Y.X.). Only those citations that both reviewers
deemed irrelevant were excluded. References with a disagreement between the two reviewers were
included for a further full review.
In the second phase of the study selection, the full content of each study obtained during the
screening stage was reviewed and assessed. We included cohort studies that reported data on the
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subjects who had used TCAs and on the participants who were not exposed to antidepressants.
The outcome variables were reported as either fractures, BMD or both. No clinical trial studies were
found to be eligible. Cross-sectional studies were excluded from this meta-analysis. Using prespecified
selection criteria and assessment protocols, two investigators (Q.W. and Y.X.) independently assessed
the full content of each article in English and Chinese. Articles in other languages were reviewed and
evaluated by additional investigators who had the corresponding multilingual expertise, using the same
criteria and assessment protocol. Areas of disagreement or uncertainty were resolved by consensus.
We only included studies that reported the hazard ratio (HR) or risk ratio (RR) of fractures, or/and the
BMD change associated with TCA use. HR is broadly equivalent to RR [38]; thus, we approximated
HRs as RRs. The agreement between investigators was evaluated using the κ statistic, a robust statistic
for testing for interrater reliability [39]. The kappa value was calculated using the following formula:
κ = [Pr(a) − Pr(e)]/[1 − Pr(e)], (1)
where Pr(a) is the actual observed agreement and Pr(e) is the expected agreement.
2.3. Study Appraisal
We evaluated the methodological quality of the included studies by using the Newcastle-Ottawa
Scale [40]. As recommended by the MOOSE study team [33], the quality scores were not used as
weights for the corresponding studies in the meta-analyses. Instead, the quality scores were used in a
subgroup analysis (>7 vs. ≤7).
2.4. Data Abstraction
We used the data abstraction form modified from our previous meta-analysis [24].
Two investigators (Q.W. and Y.X.) independently abstracted all data through the use of the data
abstraction form. No major disagreements or discrepancies arose between the two investigators;
minor differences were resolved by rechecking the original reports and by discussion. We abstracted
the following information from each study: the study characteristics (the names of authors, the year
of the publication and the journal if applicable, and the country where the research was conducted),
the study design, the study setting, the inclusion criteria, the sample size and duration of the follow-up,
the participants’ characteristics (age, gender and race, if available), the outcomes (fractures or
BMD change) and corresponding regions and ascertainment methods, the assessment of TCA use,
the statistical analysis methods, and the estimates of the effect size (adjusted RR, HR, BMD change and
their 95% CIs). For the overall pooled analysis, when original reports presented multiple estimates,
we selected the effect size that adjusted for the most confounders, the estimate derived from the
larger sample size, the estimate from current TCA users, and the estimate from an osteoporotic
fracture, if applicable. Corresponding estimates from the subgroup analyses in the original studies
were abstracted when appropriate. We did not contact the authors of the original studies because no
additional information was required.
2.5. Statistical Analysis
We used the confounder-adjusted RR to measure the association between TCA use and fracture
risk. HR was considered equivalent to RR. For studies that reported the estimates by subgroups
only, the overall effect size was estimated by a meta-analysis of the reported subgroup’s estimates.
To normalize the data distribution and to stabilize the variance, we transformed HRs or RRs into their
natural logarithms [41] for the pooled meta-analysis. We derived the variance of the natural logarithm
of the HR or RR from the corresponding 95% CIs provided by the original reports. To calculate the
overall estimated RR and BMD change, we weighted each included study by the reciprocal of the
corresponding variance reported in the original studies. Both frequentist and Bayesian hierarchical
random-effects models were utilized for the synthesis analysis. In the frequentist meta-analysis,
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the DerSimonian-Laird method [42] was used to calculate the pooled RR and variance. In the Bayesian
meta-analysis, Gaussian distribution with an unknown effect size (θi) and known within-study variance
δ2i was assumed for each log RR (denoted as ϕi). The set of θi across the original studies was also
assumed to follow a Gaussian distribution, with an unknown mean (µ) and across-study variance (τ2),
where µ was the estimate of the overall log RR and τ2 was a measure of the between-study variation.
The prior distribution of τ2 was assumed to follow an improper uniform distribution, and the prior
distribution for τ2 was assumed to be non-informative. The probabilities that TCA use increases
fracture risk by more than 0%, 10% or 20% were estimated and reported.
To assess the robustness of our estimates, we conducted several prespecified sensitivity analyses.
The effects of TCAs on fracture risk were calculated with different inclusion criteria, including using
TCA as the primary exposure, using osteoporotic fractures as the outcome, and studies focusing on
people younger than 65 years old. The Cochran Q statistic [43] and the Higgins index I2 were employed
to assess heterogeneity [44]. We applied the random-effects model for this meta-analysis because of the
observed heterogeneity between the original studies.
To determine whether demographic and clinical variables modified the effect of TCAs on fracture
risk, we conducted several prespecified subgroup analyses. These variables included the anatomical
site of the fracture, adjustment of fracture-related confounders (BMD, smoking, osteoporosis), year
of publication and study location. As most studies did not specify race/ethnicity and others used
multiethnic populations, a subgroup analysis for race/ethnicity was not performed. We conducted a
cumulative meta-analysis by performing sequential random-effects pooling, beginning with the earliest
qualified report. Each subsequent meta-analysis summarized all eligible reports in the preceding
years. To demonstrate the effect of adding reports on the pooled effect size, we presented results
chronologically in a forest plot. A multivariate meta-regression analysis was not performed because the
number of eligible studies was small, and because some key variables, such as gender and race/ethnicity,
were not available in some original reports.
To examine the potential for publication bias, we constructed a funnel plot by plotting RRs against
their standard errors [45]. We also used the Begg and Mazumdar rank correlation test [46] to examine
the significance of publication bias. Furthermore, we employed the trim-and-fill method to estimate
and adjust for the potential effects that nonpublished studies might have had on the estimated effect
size. We used R statistical software (Version 4.0, Core Team, Vienna, Austria) for the data analysis.
A p-value of 0.05 or less was considered statistical significant.
3. Results
The study selection flow is illustrated in Figure 1. After removing duplicate references from
different databases, we found a total of 6336 potential references. After the two investigators (Q.W. and
Y.X.) screened titles and abstracts of all these references, 137 full-text research articles were retrieved
and assessed for eligibility. The agreement between the two investigators was modest at this initial
screening stage (κ = 0.70). After reviewing all full-text articles, eight studies with fracture data met
the inclusion criteria. The agreement between the two investigators was good at this second stage
(κ = 0.93). No related randomized controlled trials were eligible, and no studies with BMD outcomes
were qualified. All eight included studies were published in English.
Table 1 showed participants’ characteristics and related information from the eight eligible cohort
studies. Each included study was controlled for confounding effects of age and sex (if applicable).
The mean follow-up period ranged from five to ten years. Of the eight studies, three were conducted
only on persons aged ≥65 years [23,28,30], four of the eight were performed in Europe [26,27,29,31],
three were conducted in North American [23,25,30], and one reported results from different regions [28].
Figure 2 shows the pooled RR estimated through the use of both frequentist and Bayesian
approaches. It demonstrates the fracture risk (RR and 95% CI or CrI) associated with TCA treatment
in each original study and all studies combined. Compared with patients who had not taken TCAs,
those who had taken TCAs had an overall RR of 1.23 (95% CI, 1.06–1.42) in the frequentist approach
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and 1.24 (95% CrI, 1.01–1.56) when using the Bayesian method. The probabilities that TCA use
increased fracture risk by more than 0%, 10% and 20% were 98%, 89% and 63%, respectively.
Significant heterogeneity was observed among the eight studies in this meta-analysis, as the Cochran
Q statistic was significant (p < 0.01), and the Higgins I2 index was 82%.
J. Clin. Med. 2020, 9, x FOR PEER REVIEW 5 of 17 
 
Significant heterogeneity was observed a ong the eight studies in this meta-analysis, as the Cochran 
Q statistic was significant (p < 0.01), a  e Hig ins I2 index was 82%. 
 
Figure 1. PRISMA flow chart of the study selection (BMD, bone mineral density, TCAs, tricyclic 
antidepressants). 
Figure 1. PRIS A flow chart of the study selection (BMD, bone mineral density, TCAs,
tricyclic antidepressants).
J. Clin. Med. 2020, 9, x FOR PEER REVIEW 1 of 17 
J. Clin. Med. 2020, 9, x; doi: FOR PEER REVIEW www.mdpi.com/journal/jcm 
 
Figure 2. Fracture risk associated with tricyclic antidepressants use for individual studies, and all 
eligible studies combined by using frequentist and Bayesian approaches. (CI, confidence interval; CrI, 
Credit Interval). 
The estimated fracture risk associated with TCA use changed little when studies had different 
inclusion criteria (Table 2). For example, the overall estimated RR did not alter when only studies 
using TCA as the primary exposure were included (RR, 1.23; 95% CI, 1.05–1.43). The effect size 
decreased slightly to 1.20 (95% CI, 1.00–1.43) when studies that reported HR for the risk estimation 
were included. The effect size increased slightly to 1.37 (95% CI, 1.04–1.47) when studies with 
osteoporotic fractures as the outcome were included. After the exclusion of three studies that only 
included persons older than 65 years, the overall RR increased slightly to 1.25 (95% CI, 1.04–1.52). The 
cumulative meta-analysis (Figure 3) by the frequentist method demonstrated that the pooled RR 
associated with TCA use fluctuated over time; however, it was consistently significant since 2011, as 
suggested by the fact that the corresponding 95% CIs did not include 1. 
Table 2. Risk ratio of fracture associated with treatment of tricyclic antidepressants according to 





(95% CI) p-Value 
All studies 8 1.23 (1.06–1.42) 0.0065 
All Studies (estimated by Bayesian approach) 8 1.24 (1.01–1.56) 0.02 
Studies with TCA use as the primary exposure a 7 1.23 (1.05–1.43) 0.0085 
Studies that used HR for risk estimation b 7 1.20 (1.00–1.43) 0.05 
Studies that used osteoporotic fractures as 
outcome c 
6 1.37 (1.30–1.45) 0.0001 
Studies with participants ≤65 years d 5 1.25 (1.04–1.52) 0.02 
The frequentist approach and random-effect model were used for analysis unless noted otherwise. 
Abbreviations: CI, confidence interval; TCA, tricyclic antidepressant. a excludes Richards et al. [25] 
(2007). b excludes Bakken et al. [29] (2013). c Excludes Couplant et al. [27] (2018) and Tamblyn et al. 
[28] (2020). d excludes Diem et al. [23] (2011), Cauley et al. [30] (2016) and Tamblyn et al. [28] (2020). 
Figure 2. Fracture risk associated with tricyclic epre sants use for individual studies, and all
eligibl studies combined by using entist and Bayesian approaches. (CI, confidence interval;
CrI, Credit Interval).
J. Clin. Med. 2020, 9, 2584 6 of 14




Assessment Outcome Assessment Outcomes
Mean Follow-Up,








Interview Yearly questionnaire Fragility fracture 5
Age, total hip BMD, modified Charlson
index, prevalent vertebral deformity,
prevalent fragility fractures at baseline,
cumulative lifetime estrogen use
in women.
The Canadian Institutes of
Health Research, Merck Frosst
Canada Ltd., Eli Lilly Canada
Inc, Novartis Pharmaceuticals
Inc, The Alliance for Better
Bone Health, The Dairy








dispensing records By a medical specialist Non-vertebral 8.4
Age, sex, depression during follow-up,
disability category, and
lower-limb disability.
No external funding was









fractures every four months by
postcard or telephone, all
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information on alcohol use was not
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The Canadian Institutes of
Health Research (CIHR)
operating grant MOP-111166
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Fractures in Men Study; FNBMD, femur neck bone mineral density; NSAIDs, nonsteroidal anti-inflammatory drugs.
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The estimated fracture risk associated with TCA use changed little when studies had different
inclusion criteria (Table 2). For example, the overall estimated RR did not alter when only studies using
TCA as the primary exposure were included (RR, 1.23; 95% CI, 1.05–1.43). The effect size decreased
slightly to 1.20 (95% CI, 1.00–1.43) when studies that reported HR for the risk estimation were included.
The effect size increased slightly to 1.37 (95% CI, 1.04–1.47) when studies with osteoporotic fractures as
the outcome were included. After the exclusion of three studies that only included persons older than
65 years, the overall RR increased slightly to 1.25 (95% CI, 1.04–1.52). The cumulative meta-analysis
(Figure 3) by the frequentist method demonstrated that the pooled RR associated with TCA use
fluctuated over time; however, it was consistently significant since 2011, as suggested by the fact that
the corresponding 95% CIs did not include 1.
Table 2. Risk ratio of fracture associated with treatment of tricyclic antidepressants according to
different inclusion criteria.
Studies Included Number of Studies Relative Risk (95% CI) p-Value
All studies 8 1.23 (1.06–1.42) 0.0065
All Studies (estimated by Bayesian approach) 8 1.24 (1.01–1.56) 0.02
Studies with TCA use as the primary exposure a 7 1.23 (1.05–1.43) 0.0085
Studies that used HR for risk estimation b 7 1.20 (1.00–1.43) 0.05
Studies that used osteoporotic fractures as outcome c 6 1.37 (1.30–1.45) 0.0001
Studies with participants ≤65 years d 5 1.25 (1.04–1.52) 0.02
The frequentist approach and random-effect model were used for analysis unless noted otherwise. Abbreviations: CI,
confidence interval; TCA, tricyclic antidepressant. a excludes Richards et al. [25] (2007). b excludes Bakken et al. [29]
(2013). c Excludes Couplant et al. [27] (2018) and Tamblyn et al. [28] (2020). d excludes Diem et al. [23] (2011),
Cauley et al. [30] (2016) and Tamblyn et al. [28] (2020).
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Figure 3. Cumulative random-effects meta-analysis of TCA effects on the risk of fracture.
The DerSimonian–Laird method was used for analysis.
Table 3 summarizes the effects of TCA on the risk of fracture in subgroup analyses. The risk of
fracture was higher among studies focusing on hip/femur fractures (RR, 1.36; 95% CI, 1.26–1.47) when
compared to nonvertebral fractures (RR, 1.28; 95% CI, 1.00–1.64). We also found that the risk of fracture
was higher when adjusted for BMD when compared to the estimate without a BMD adjustment.
Moreover, studies conducted before 2015 (RR, 1.35; 95% CI, 1.19–1.51) and completed outside of
the USA (RR, 1.20; 95% CI, 1.00–1.45) had a significant association between TCA use and fracture.
The increased risk associated with TCA use was more evident in several subgroups (Table 3), but no
significant between-group differences were found (all p > 0.15). A moderate to high heterogeneity was
observed in most of these subgroup analyses.
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Table 3. Fracture risk associated with the use of tricyclic antidepressants in the subgroups analysis
defined by the following characteristics: anatomical site of fracture, confounder adjustment, years of
publication, study location and quality score.
Studies Included Number of Studies Risk Ratio (95% CI) p-Value Between-Group p-Value
Anatomical site of a fracture
Non-spine/Non-vertebral 2 1.28 (1.00–1.64) 0.049
0.59Hip/Femur 4 1.36 (1.26–1.47) <0.0001
Adjusted for BMD
Yes 3 1.27 (1.01–1.61) 0.04
0.72No 5 1.2 (1.00–1.45) 0.049
Adjusted for smoking
Yes 4 1.22 (0.95–1.55) 0.11
0.84No 4 1.26 (0.99–1.67) 0.06
Adjusted for osteoporosis
Yes 4 1.09 (0.83–1.44) 0.53
0.16No 4 1.35 (1.22–1.51) <0.0001
Year of publication
<2015 4 1.35 (1.23–1.46) <0.0001
0.31
≥2015 4 1.16 (0.89–1.53) 0.27
Location
USA 2 1.47 (0.83–2.62) 0.19
0.51International 6 1.20 (1.00–1.45) 0.04
Quality score
≤7 5 1.24 (1.05–1.46) 0.009
0.96
>7 3 1.25 (0.86–1.82) 0.23
No publication bias was observed in this meta-analysis, as indicated by the visual inspection of the funnel plot
(Figure 4), and the Begg’s test (p = 0.80) indicated that symmetry existed in the funnel plot. Additionally, the use of
trim-and-fill correction procedures did not alter the results.
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4. Discussion
The present meta-analysis demonstrated hat TCA use is associ ted with a significantly increased
risk of fracture in cohort studies. The association between TCA use and fracture risk was consistent
and significant in both frequentist and Bayesian meta-analyses, as well as in all sensitivity analyses and
multiple subgroup analyses, which suggested that our findings were robust. Although the fracture
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risk associated with TCA use found in this meta-analysis was moderate, the estimated absolute risk
differences associated with TCA medications could be substantial, given that depression is a prevalent
mental illness on a global scale, and that TCAs are still the major prescribed medicines for depressions
that have not responded to safer agents or for which safer alternatives are not available [8]. Thus the
fracture risk associated with TCA use may have important implications for clinical medicine and
public health.
The present study results are consistent with our previous meta-analysis, according to which
TCA medication may convey an increased risk of fracture [24]. Our prior meta-analysis included
both case-control and cohort studies; however, case-control studies are commonly limited by recall
bias and might lead to an inaccurate estimate of the associated effect size. Furthermore, the previous
meta-analysis was published eight years ago, and thus it was not able to integrate findings from
recently published studies [27–31]. Therefore, our current study focused on the integration of related
cohort studies only, and we were able to include four large and well-designed studies [27–31] that
have not been included in any prior meta-analyses. We replaced the original study by Lewis et al. [19]
in the previous meta-analysis with an updated report by Cauley et al. [30] because both studies used
the same data source, and the updated report [23] had a larger sample size and would provide more
reliable results.
The findings from the Bayesian meta-analysis were consistent with the results generated from the
classical meta-analysis approach. Moreover, the Bayesian meta-analysis provided the probabilities that
TCA use increases fracture risk by 10% and 20%. The calculated probabilities at different risk levels offer
essential information to physicians in order to help them make clinical intervention decisions regarding
the prescription of TCAs for patients. Heretofore, such information was impossible to generate when
using a conventional meta-analysis methodology alone.
We observed some variations in the estimated fracture risk associated with TCA use in the subgroup
meta-analysis. Fracture risk associated with TCA use in studies that focused on hip/femur fracture
outcomes was significantly higher than that in the nonvertebral fracture group. Since hip fracture is
more likely to be influenced by falls [24,47], TCAs are highly anticholinergic, often causing sedation
and postural instability, both of which appear to increase the likelihood of falls. Although subgroup
analyses showed different risk estimates associated with TCA use between the examined subgroups,
the estimated risk was not significant in certain groups because of the small number of studies qualified
for this meta-analysis. Due to the same reason, the difference between subgroups was not statistically
significant in all subgroup analyses. Therefore, additional extensive cohort studies are warranted to
investigate whether demographic and clinical variables modify the effect of TCA use on fracture risk.
Finally, although our cumulative meta-analysis showed that the pooled estimate fluctuated with time,
it showed that since 2011 there has been a consistent and significant association between TCA use and
an increased risk of fracture. Additional extensive cohort studies are warranted. The future cumulative
meta-analysis should include more eligible cohort studies in order to stabilize the estimate of fracture
risk associated with TCA use.
The underlying mechanism of how TCA medication influences fracture risk remains unclear.
The increased risk of fracture might be caused by bone loss and a higher propensity to fall. Prior research
found a significant association between antidepressant use and an increased risk of falls among the older
population [48,49]. TCA medication may cause ataxia, impaired psychomotor function, syncope and
additional falls among older adults [50]. In addition, most patients have decreased blood pressure at
the initial stage of TCA treatment [51,52], and the risk of falling may increase because of a reduced blood
pressure. On the other hand, TCA treatment may also increase patients’ heart rates [53], which leads
to an influence on the cardiac output and a decreased blood flow to the central nervous system,
then causing confusion and delirium. These adverse effects often lead to an increase in the propensity
to fall and thus create an increased fracture risk.
The adverse effects described above make TCAs an inappropriate psychotropic drug for older
patients. The Beers Criteria for Potentially Inappropriate Medication Use in Older Adults and Screening
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Tool of Older Persons’ potentially inappropriate Prescriptions (STOPP) [50,54] recommended avoiding
TCAs in older adults unless safer alternatives were not available. Although TCAs have gradually been
replaced by SSRIs and other antidepressants with increased safety, TCA remains a good choice for
some patients whose depression has not responded to treatment with less toxic agents [8]. As one of
the top choices for pharmacologic interventions in treating clinical depression in the past decades,
TCAs have been a more successful treatment for melancholic depression than other antidepressant drug
classes [55]. To the best of our knowledge, the present study is the most comprehensive meta-analysis
to date to investigate the association between TCA use and fracture risk in cohort studies. Our analysis
results from sensitivity analysis, subgroup analysis and cumulative meta-analysis have demonstrated
the robustness of the significant association between TCA use and fracture risk.
There are several limitations associated with our meta-analysis. First, because of the limited
number of studies that met the inclusion criteria (n = 8), we were not able to perform a multivariate
meta-regression analysis to further examine the sources of heterogeneity observed in this meta-analysis.
Nonetheless, as described above, we conducted numerous subgroup analyses to determine the
variations of the estimated risk by key variables and risk factors. Heterogeneity may be partially
caused by subgroup differences in the anatomical site, year of publication, and the study sample
and location, as well as by the adjustment for BMD, smoking or osteoporosis. Second, we were not
able to assess the risks of falls in this meta-analysis because few eligible original studies accounted
for the risk factor of falls. Nonetheless, falls remain an essential potential etiology in the association
between TCA use and the risk of fracture. Third, we were not able to assess the effects of different
doses of TCA on fracture risk, as the TCA dose was not available in most original studies of this
meta-analysis. Fourth, other medications, including glucocorticoids [56,57] and anticonvulsants [58],
were also reported to be associated with fracture risk. However, such information was not available in
most original studies. Thus we were not able to assess the impact of these confounders on fractures in
this meta-analysis. Finally, we approximated HRs as RRs in our current meta-analysis. HR and RR
are different, although they are deemed broadly equivalent and have been used interchangeably in
much meta-analysis research [59–61]. To examine the possible impact on our findings, we conducted
a sensitivity analysis that included studies reporting HR only: the corresponding pooled effect size
changed slightly and remained significant. Additional research is warranted to examine the role of
these factors in the association between TCA treatment and fracture risk.
5. Conclusions
Our study suggests that the use of TCAs is associated with an increased risk of fracture.
The increased risk associated with TCA use is moderate but may have a substantial clinical impact.
Nonetheless, further extensive cohort investigations are warranted, given the variance observed in the
subgroup analysis and the unstable estimate found in the cumulative meta-analysis. TCA should be
prescribed with caution in the clinic. Fracture risk should be monitored in patients with TCA treatment.
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Appendix A
Medical Literature Search Strategy; 1 bone fractures.mp. or exp Fractures, Bone/. 2 exp
Osteoporosis/ or osteoporosis.mp. 3 bone mineral density.mp. or exp Bone Density. 4 bone density.mp.
5 bone fracture.mp. 6 bmd.mp. 7 exp “Bone and Bones”/ or bone loss.mp. 8 bone#.mp. 9 1 or 2 or
3 or 4 or 5 or 6 or 7 or 8. 10 tricyclic antidepressants.mp. or exp Antidepressive Agents, Tricyclic/
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11 exp Antidepressive Agents/ 12 antidepressant#.mp. 13 amitriptyline.mp. or exp Amitriptyline/
14 nortriptyline.mp. or exp Nortriptyline/ 15 protriptyline.mp. or exp Protriptyline/ 16 desipramine.mp.
or exp Desipramine/ 17 doxepin.mp. or exp Doxepin/ 18 trimipramine.mp. or exp Trimipramine/
19 imipramine.mp. or exp imipramine/ 20 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 21 9
and 20. 22 limit 21 to humans.
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